Last reviewed · How we verify
NCT03430934
Non-invasive Fluorescent Imaging System for Imaging Mohs Tumor
EARLY_PHASE1 trial testing NAVI mapping with Indocyanine green in Skin Cancer in 11 participants. Completed in 1 August 2019.
1 August 2019
Quick facts
| Lead sponsor | University of Missouri-Columbia |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | device feasibility |
| Enrollment | 11 |
| Start date | 1 July 2018 |
| Primary completion | 1 August 2019 |
| Estimated completion | 1 August 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- NAVI mapping with Indocyanine green
Conditions studied
- Skin Cancer — all drugs for Skin Cancer →
Sponsor
University of Missouri-Columbia
Who can join
18 and older, any sex, with Skin Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to correlate traditional histological Mohs tissue mapping of a cutaneous tumor with the ICG-mapping procedure. The use of intradermal ICG in a cutaneous tumor during MMS followed by visualization using a fluorescent imaging system could allow surgeons to directly visualize, and roughly map the extent of a primary skin cancer and plan the Mohs procedure (i.e. the initial excision size and subsequent layer widths) accordingly.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03430934
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Skin Cancer
Currently open trials in the same condition.
- NCT07288073 — TIL Therapy in cSCC and MCC · Phase 2 · recruiting
- NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT06932172 — Artificial Intelligent Decision Support for Skin Cancer Diagnostics in Primary Care · NA · recruiting
- NCT07510061 — Title: ICARUS - Psycho-physiological Profiling of Low and High Heat-resilient Individuals · NA · recruiting
- NCT07200544 — Meloxicam in Mohs Micrographic Surgery · Phase 4 · recruiting
Other University of Missouri-Columbia trials
Trials by the same sponsor.
- NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
- NCT07385105 — Evaluation of Cognitive Behavioral Therapy for Insomnia (CBT-I) in Individuals With Mild Traumatic Brain Injury (mTBI) · NA · not yet recruiting
- NCT07067502 — Impact of Biphasic Cuirass Ventilation Compared to Non Invasive Ventilation in High Risk Extubations · NA · not yet recruiting
- NCT07424079 — Metacognitive Strategy Training Intervention for Transition-Age Youth With Cerebral Palsy · NA · not yet recruiting
- NCT07216196 — The Feasibility of a Remote Problem-Solving Intervention for Autistic Adolescents or Young Adults and a Caregiver · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03430934 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Missouri-Columbia
- Last refreshed: 9 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03430934.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing